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Death receptor 6 is a novel plasmacytoid
dendritic cell-speciﬁc receptor and modulates
type I interferon production
Dear Editor,
Plasmacytoid dendritic cells (pDCs) are the professional
type I interferon-producing cells of the immune system,
which rapidly produce massive amounts of type I interferons
(IFN-I) in response to viruses or other nucleic acids ligands
through selectively expressed toll-like receptor (TLR)-7 and
TLR9 (Siegal et al., 1999). The activation of pDCs not only
inhibits virus replication, but also regulates the function of
other immune cells and links the innate and adaptive
immunity (Liu, 2005). The local accumulation of pDCs has
been reported in both suppressive and overactive immune
status (Swiecki and Colonna, 2010), which highlights the
importance of characterizing the molecular mechanisms
underlying the functional specialization of pDCs in IFN-I
production.
Death receptor 6 (DR6) is a member of death receptor
family, which belongs to the tumor necrosis factor receptor
superfamily (TNFRSF). It is reported that DR6 plays vital
roles in axon pruning, neuron death, and negatively regu-
lates oligodendrocyte survival, maturation and myelination in
neural system (Nikolaev et al., 2009; Mi et al., 2011). DR6-/-
mice exhibit enhanced CD4+ T cell proliferation, Th2
cytokines production and B cell expansion, survival, and
humoral responses, which imply that DR6 plays important
roles in murine immune responses (Liu et al., 2001; Schmidt
et al., 2003). However, the expression proﬁles and functions
of DR6 in human immune system remain largely unknown.
We found that DR6 was highly expressed in human pDCs
comparing with other blood cells by microarray analysis
(Fig. 1A). Additionally, we found that among the 6 death
receptors, including TNFR1, CD95, DR3, DR4, DR5 and
DR6, pDCs exclusively expressed DR6 but not others
(Fig. 1A). To conﬁrm the expression of DR6 in pDCs, we
performed quantitative real time-PCR analysis on several
cell types from peripheral blood. Consistently, DR6 mRNA
was preferentially expressed on human pDCs (Fig. 1B).
To verify the expression of DR6 on pDCs at the protein
level, we used αDR6, homemade DQM3 (Hu et al., 2014), to
stain fresh human PBMC. BDCA2 was used to identify pDCs
(Dzionek et al., 2000). Our results showed that almost all
DR6 positive cells were BDCA2 high cells, suggesting that
DR6 is indeed speciﬁcally expressed on pDCs at protein
level (Fig. 1C). In addition, we also demonstrated that pDCs
rapidly down-regulated the expression of DR6 upon in vitro
culture with CpG-ODN or IL-3 as early as 3 h after activation
(Figs. 1D and S1A). GEN2.2 is a human leukemic cell line
and similar to human primary pDCs both phenotypically and
functionally (Chaperot et al., 2004). Our Data showed that
DR6 was also downregulated by CpG-ODN stimulation in
GEN2.2 cells. However, there was no obvious DR6 down-
regulation when GEN2.2 cells were cultured for up to 24 h in
medium in the absence of stimulation (Fig. S1B). Therefore,
our results point out that DR6 is a novel marker of pDCs and
rapidly downregulated upon activation.
To analyze the function of DR6 in human pDCs, we per-
formed knockdown experiments in GEN2.2 cells. We con-
structed lentiviral vectors expressing two short hairpin RNAs
(shRNA-1 and shRNA-2) speciﬁc for DR6 and established
stably transduced GEN2.2 cell lines. The knockdown efﬁ-
ciency was conﬁrmed by quantitative real time-PCR
(Fig. 2A). DR6 knockdown cells (shRNA-1 or shRNA-2) and
control cells (shRNA-c) were treated with CpG-ODN and the
secretion of IFN-α and IL-6 was examined by ELISA.
Knockdown of DR6 by shRNA-1 or shRNA-2 signiﬁcantly
reduced IFN-α production in response to CpG-ODN
(Figs. 2B, 2D, S2A and S2B), while it had marginal effect on
IL-6 production (Fig. 2C and 2E). Besides, our data indicated
that knockdown DR6 also signiﬁcantly reduced CpG-B
induced IFN-β production (Fig. S2C). These ﬁndings suggest
that DR6 plays an important role in IFN-I production, but not
in the production of proinﬂammatory cytokines.
To further investigate the roles of DR6 in regulating
interferon responses, we tested the ability of DR6 to activate
IFN-α promoter by a reporter assay. HEK293T cells were
transiently transfected with the various amounts of expres-
sion plasmid encoding full length DR6 (DR6-FL) or intracel-
lular-domain deleted DR6 (DR6-EX) along with IFN-
regulatory factor 7 (IRF7) (Kawai et al., 2004) and a reporter
plasmid driven by IFN-α4 promoter. Luciferase activity was
measured at 24 h post transfection. Overexpression of
DR6-FL caused activation of IFN-α4 promoter in a dose-
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dependent manner, whereas there was little induction of
IFN-α4 promoters activity when DR6-EX was overexpressed
(Fig. 2F). These data indicate that DR6 regulating IFN-I
production depends on its intracellular domain.
It is well established that IRF7 nuclear translocation is the
key event upon stimulation pDCs with CpG-ODN, which
eventually leads to the production of IFN-I (Honda et al.,
2005a; Honda et al., 2005b). To investigate the requirement
of DR6 for CpG-ODN induced nuclear translocation of IRF7,
we isolated nuclear fractions following CpG-ODN treatments
and monitored the nuclear localization of IRF7 by Western
blot. After CpG-ODN stimulation, IRF7 displayed increased
distribution in the nucleus, while knockdown of DR6 in
GEN2.2 cells signiﬁcantly diminished the nuclear localization
of IRF7 (Fig. 2G). This result suggests that DR6 is necessary
for CpG-ODN induced IRF7 nuclear translocation.
In summary, in this study, we report for the ﬁrst time that
DR6 is a novel human pDC-speciﬁc receptor. In addition, we
demonstrated that knockdown DR6 by shRNA in human
pDCs cell line GEN2.2 signiﬁcantly diminished the CpG-
ODN induced IRF7 nuclear localization and IFN-I production.
Therefore, as a regulator of interferon production by pDCs,
DR6 may be a potential targets for regulating IFN-I produc-
tion by pDCs.
Pan et al. (1998) reported that DR6 overexpression in
some cell lines induced NF-κB and JNK activation. As a
matter of fact, we found that both NF-κB and JNK activation
upon CpG-ODN treatment were inhibited in DR6 knockdown
cells (unpublished data). We hypothesize that DR6 might
regulate TLR-9 induced IRF-7 translocation and IFN-I pro-
duction through NF-κB activity and/or JNK activation, while
the exact attribution needs further deep investigation.
DR6 belongs to death receptor family which initiates
cytotoxic signals or regulate cell proliferation and survival
(Guicciardi and Gores, 2009). During our research, the cell
growth rates of GEN2.2 did not change upon knocking-down
DR6 by shRNA, while DR6 overexpression on GEN2.2 does
increase cell death (data not shown). Thus, the roles of DR6
in pDCs development and activation need to be further
characterized.
N-terminal of amyloid precursor protein (N-APP) was
































































































Figure 1. DR6 is speciﬁcally expressed on human pDCs. (A) The relative expression of death receptors in different subsets of
peripheral blood leukocytes was compared by cDNA array. (B) Human total PBMC, pDCs, B cells, T cells, NK cells, monocytes were
isolated and total RNA was puriﬁed and reverse transcribed. The cDNA was subjected to quantitative real-time PCR analysis and the
arbitrary units of gene expression were normalized with GAPDH. Results are the mean value of duplicates, and error bars represent
standard deviations (SD). (C) Human PBMCs were incubated with isotype control (left panel) or α-DR6 (right panel) followed by biotin
labeled rat anti-mouse IgG and streptavidin-PE, then both samples were stained with BDCA2-APC. (D) pDCs were cultured with
CpG-B (1 μmol/L) or IL-3 (20 ng/mL) for 3∼24 h and the cells were harvested and the levels of DR6 RNA were evaluated by
quantitative real-time PCR.
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neurons (Nikolaev et al., 2009). However, DR6 negatively
regulates survival and maturation through the caspase-3
pathway by a mechanism independent of N-APP binding in
oligodendrocyte (Mi et al., 2011). Recently, it is reported that
high-afﬁnity binding to DR6 requires a C-terminal portion of
the APP ectodomain rather than its N-terminal domain
(Olsen et al., 2014). However, if APP regulates pDCs
development and functions through DR6 has not been
characterized. Furthermore, it will also be necessary to
address if other DR6 ligands exist and regulate DR6 sig-
naling in pDCs in human immune system.
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Figure 2. DR6 regulates type I IFN-production by mediating CpG-ODN induced IRF7 nuclear translocation. (A) GEN2.2 cells
were transduced with lentiviral vectors carrying either scrambled shRNA (shRNA-c) or shRNA targeting DR6 (shRNA-1 or shRNA-2)
and stable cell lines were generated. The knockdown efﬁciency was conﬁrmed by quantitative real-time PCR. (B–E) DR6 knockdown
cells and control cells were stimulated with CpG-B for 20 h. Levels of IFN-α and IL-6 in the culture supernatants were examined by
ELISA. (F) HEK293T cells were transiently transfected with IRF7 and IFN-α4 promoter-driven luciferase reporter plasmid together
with increasing amounts of expression vectors of DR6 (DR6-FL) or truncated DR6 without intracellular domain (DR6-EX). Renilla was
used as an internal control for transfection efﬁciency. Promoter activity was measured 24 h post transfection by luciferase assay.
(G) DR6 knockdown cells (shRNA-2) and control cells (shRNA-c) were stimulated with CpG-B for 4 h. Nuclear fractions were isolated
and immunoblotted with anti-IRF7 antibody. Histone H3 was used as a loading control.
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This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
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